NCT01124253已完成3 期
Phase III Study of Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
Shanghai Jiao Tong University School of Medicine1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2007年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- overall survival(OS)
研究概览
简要总结
This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell lung cancer.
详细描述
It is an open labelled, randomized, mono-center phase III clinical trail.A total of 250 patients with resected stage IB to stage IIIA non-small cell lung cancer will either the group of vinorelbine plus cisplatin plus endostar or the group of vinorelbine plus cisplatin randomly. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimens.The major inclusive criteria are pathological confirmed non-small cell lung cancer after complete resection and can tolerate chemotherapy safely.The tissue and blood samples will be banked for further investigation. All of the enrolled patients will be followed up until death or over 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed non-small cell lung cancer, the pathology type includes squamous cell carcinoma, adenocarcinoma, large-cell carcinoma, and any mixed type of the 3 types mentioned above.
- •Stage IB-IIIA non-small cell lung cancer, tumor was completely resected (The type of surgery including lobectomy, left side pneumonectomy,bi-lobectomy).
- •The time from surgery to first dose of adjuvant chemotherapy are mandatory between 4-8 weeks.
- •No evidence of tumor relapse prior to adjuvant therapy.
- •Age 18-70, Eastern Cooperative Oncology Group(ECOG) performance status 0-
- •Normal hematologic function.Renal function , hepatic and cardiac function will be within the acceptable ranges as following:serum bilirubin, aspartate aminotransferase(AST)and alamine aminotransferase(ALT)levels below 1.5 times of normal value.
- •No history of chemotherapy or radiotherapy;
- •The patient should have well compliance for chemotherapy and follow up
- •Informed consent should be obtained before treatment.
排除标准
- •The histological or cytological documents do not match the inclusion criteria.
- •Right side pneumonectomy or any kind of incompletely resected surgery.
- •The recruitment time are beyond 8 weeks from surgery.
- •Any concurrent acute or chronic systemic diseases or psychiatric diseases, which might both increase the risks of the research itself or the medical therapy and influence the research results analysis. The researchers can make a judge for the following conditions to tell whether they are fit for this research:Uncontrolled high blood pressure, unstable angina , myocardial infarction , uncontrolled arrhythmia,or congestive heart failure with clinical symptoms within 12 weeks before randomization.Evidence of anemia from electrocardiographic manifestation or heart valve disease with confirmed clinical diagnosis.Clinically significant active infection state due to bacteria, virus and fungi invasion. Patients with grade II arrhythmia, grade II myocardial anemia, grade II abnormal cardiac troponin T, grade II high blood pressure or left ventricle ejection fraction (LVEF) less than 50 percent according to CTC 3.0 are not permitted to enrol the study.
- •women with pregnant or lactation.
- •Before enter the group,the patients had other malignant tumors except for non-melanoma skin cancer, carcinoma in situ and cured early-stage prostate cancer.
- •With allergic constitution or possible allergic reflection to any known research drugs.
- •Poor compliance.
- •Not proper for the research according to the researchers' judgment.
研究组 & 干预措施
NP plus recombinant human endostatin
Experimental
干预措施: recombinant human endostatin (Drug)
vinorelbine plus cisplatin
No Intervention
干预措施: recombinant human endostatin (Drug)
结局指标
主要结局
overall survival(OS)
时间窗: five years
次要结局
- disease-free survival(DFS)(five years)
- the toxicity and safety(two years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung CancerNon-small Cell Lung CancerNCT00576914Chinese Academy of Sciences1,108
进行中（未招募）
2 期
VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast CancerMetastatic Breast CancerNCT00431704National Cancer Institute, Naples39
已完成
3 期
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung CancerNSCLCNCT00683514Pierre Fabre Medicament201
进行中（未招募）
3 期
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaAlveolar RhabdomyosarcomaBotryoid-Type Embryonal RhabdomyosarcomaEmbryonal RhabdomyosarcomaMetastatic Embryonal RhabdomyosarcomaMetastatic RhabdomyosarcomaSolid Alveolar RhabdomyosarcomaSpindle Cell RhabdomyosarcomaSpindle Cell/Sclerosing RhabdomyosarcomaNCT04994132Children's Oncology Group113
Unknown
2 期
Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective TrialBreast CancerNCT01528826Fudan University35